AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAIO-Studien-gGmbH
About this trial
National, retro- and prospective, observational, multicenter clinical research platform to connect clinical and genomic data of patients with advanced (locally advanced, inoperable, or metastatic) solid tumors (excluding NSCLC, SCLC, and mesothelioma) with results from multi-gene next-generation sequencing (NGS) panels (\>30 genes)
Eligibility criteria
Qualifiers
Diagnosis of advanced (i.e., locally advanced, inoperable, or metastatic) solid tumor, ineligible for curative surgery and/or curative systemic therapy
Available results of commercial or non-commercial RNA- and/or DNA-based multi-gene NGS panels with >30 genes analyzed; for non-commercial panels a list of all tested genes and multiple gene biomarkers (e.g., tumor mutational burden (TMB), microsatellite status) must be provided
Age ≥ 18 years
Signed and dated informed consent form (not applicable for inclusion of deceased patients)
Disqualifiers
Diagnosis of NSCLC/SCLC (C34) or mesothelioma (C45)
NGS results older than two years at the date of patient inclusion
Trial design
Treatments tested in this trial
- Minimal documentation
- Extended documentation
Treatment groups
3,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
AIO-Studien-gGmbH
Lead sponsor
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Collaborator
Merck Sharp & Dohme LLC
Collaborator
Janssen-Cilag G.m.b.H
Collaborator
Source ClinicalTrials.gov